India Glycols has advanced its corporate restructuring following the National Company Law Tribunal (NCLT) approval for a trifurcation of the business. The structural reorganization divides the company into India Glycols focusing on specialty chemicals, IGL Spirits covering spirits and biofuels, and Ennature Bio Pharma handling nutraceuticals and active pharmaceutical ingredients (APIs).
Market analysts note that the restructuring is designed to remove the conglomerate discount by establishing three independent, pure-play entities with distinct operational profiles. This separation is intended to provide clearer management focus and allow each business segment to pursue individual growth strategies.
Within the newly formed segments, IGL Spirits maintains a strong market position in Uttar Pradesh and Uttarakhand. The division relies on captive Extra Neutral Alcohol (ENA) production to support cost leadership. Recent financial reporting indicates that Indian Made Foreign Liquor (IMFL) revenue grew by 26 percent year-on-year to reach 1.4 million cases. The business is emphasizing a premiumisation strategy through the introduction of new products in deluxe whisky, semi-premium vodka, and white spirits, with management anticipating revenue growth to outpace volume growth.
Management projections for IGL Spirits target an EBITDA exceeding ₹500 crore in FY27E, with an expected increase to over ₹1,000 crore within the next four to five years.
The core chemical business, India Glycols, operates as a prominent global supplier of bio-based specialty chemicals and a pioneer in carbon-smart glycols and bio-based amines. The segment maintains established supply relationships with major consumer brands including Dove, L'Oréal, and Unilever.
Meanwhile, the Ennature Bio Pharma division reported a twofold quarter-on-quarter increase in its nicotine business, supported by new operational capacity at Kashipur. Management has set an EBITDA target of ₹130 to ₹150 crore for this segment over a four-to-five-year horizon.
Financial estimates for the consolidated entities project a revenue, EBITDA, and PAT Compound Annual Growth Rate (CAGR) of 12 percent, 15.4 percent, and 29 percent respectively between FY26 and FY29E. Projections also indicate an expansion in EBITDA margin to 16.9 percent by FY29E. Based on a Sum-of-the-Parts (SOTP) valuation, financial analysts have maintained a "Buy" rating with a target price of ₹1,639 per share.
"Corporate restructurings of this scale often help unlock substantial underlying value by allowing distinct business units to operate independently without the drag of a conglomerate discount. When a diversified enterprise splits into pure-play entities like specialty chemicals, spirits, and nutraceuticals, it provides investors with transparent metrics and gives management the operational clarity needed to scale individual segments effectively. Tracking the execution of these growth targets and margin expansions will be crucial for long-term shareholder value creation." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
